Zynerba Pharmaceuticals Announces Completion of Enrollment for …

DEVON, Pa., March 13, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The Company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.

In the double-blind, multi-center STAR 1 trial, 224 patients with refractory epilepsy were screened and the Company expects to exceed the target of randomizing 180 patients once the remaining patients complete the 8-week baseline period. The screen failure rate experienced for this trial has been between 10% –

... read more at: https://globenewswire.com/news-release/2017/03/13/934918/0/en/Zynerba-Pharmaceuticals-Announces-Completion-of-Enrollment-for-ZYN002-in-Two-Phase-2-Clinical-Trials-for-Epilepsy-and-Osteoarthritis.html